Institute for Organic Chemistry and Biochemistry, Technische Universität Darmstadt, Darmstadt, Germany.
Protein Engineering and Antibody Technologies, Protein Engineering and Antibody Technologies, Merck Healthcare KGaA, Darmstadt, Germany.
MAbs. 2022 Jan-Dec;14(1):2018960. doi: 10.1080/19420862.2021.2018960.
Controlled Fab arm exchange (cFAE) has proven to be a generic and versatile technology for the efficient generation of IgG-like bispecific antibodies (DuoBodies or DBs), with several in clinical development and one product, amivantamab, approved by the Food and Drug Administration. In this study, we expand the cFAE-toolbox by incorporating VHH-modules at the C-termini of DB-IgGs, termed DB-VHHs. This approach enables the combinatorial generation of tri- and tetraspecific molecules with flexible valencies in a straightforward fashion. Using cFAE, a variety of multispecific molecules was produced and assessed for manufacturability and physicochemical characteristics. In addition, we were able to generate DB-VHHs that efficiently triggered natural killer cell mediated lysis of tumor cells, demonstrating the utility of this format for potential therapeutic applications.
受控 Fab 臂交换(cFAE)已被证明是一种通用且多功能的技术,可高效生成 IgG 样双特异性抗体(DuoBodies 或 DB),目前已有多种处于临床开发阶段,其中一种产品 amivantamab 已获得美国食品和药物管理局批准。在这项研究中,我们通过在 DB-IgG 的 C 末端整合 VH H 模块来扩展 cFAE 工具包,将其称为 DB-VHH。这种方法能够以灵活的价态组合生成具有多种特异性的三特异性和四特异性分子。使用 cFAE,我们生产了多种多特异性分子,并评估了它们的可制造性和物理化学特性。此外,我们还能够生成能够有效触发自然杀伤细胞介导的肿瘤细胞裂解的 DB-VHH,证明了这种形式在潜在治疗应用中的实用性。